. A, CT scan before empirical therapy for toxoplasmic encephalitis in an HIV-infected patient. B, CT scan 2.5 years later, after immune restoration with highly active antiretroviral therapy and 8 months without maintenance therapy for toxoplasmic encephalitis.
Discontinuation of Secondary Prophylaxis for Toxoplasmic Encephalitis in Human Immunodeficiency Virus Infection After Immune Restoration with Highly Active Antiretroviral Therapy
Toxoplasma gondii is one of the leading causes of neurological morbidity and mortality in patients with advanced HIV infection. Effective therapies for primary and secondary prevention of toxoplasmic encephalitis in HIV infection have been established [1, 2] . With the introduction of highly active antiretroviral therapy (HAART), discontinuation of primary and secondary prophylaxis for opportunistic infections in patients with HIV infection and good response to HAART have become a focus of interest. We describe an HIV-infected patient with toxoplasmic encephalitis and excellent response to HAART who discontinued secondary prophylaxis for toxoplasmosis.
A 26-year-old woman with HIV infection presented to our clinic with headache in November 1996. She had acquired HIV infection in 1986 by needle exchange, and, in the following years, did not seek regular medical assistance. She had not received any prophylaxis for opportunistic infections or treatment with antiretroviral drugs. Physical examination showed no neurological deficits. A CT scan revealed a 2.8-cm diameter solitary hypodense cerebral lesion with perifocal edema on the right parietotemporal hemisphere (figure 1A); this lesion was suspected to be toxoplasmic encephalitis. IgG antibodies to T. gondii were positive at 34 U/mL, her CD4 cell count was 29/ mm 3 , and the plasma viral load was 302,000 copies/mL. The patient was empirically treated with pyrimethamine, sulfadiazine, and leucovorin.
Four weeks later, a control CT scan showed regression of both the cerebral lesion and the perifocal edema. Because of a severe rash, sulfadiazine was changed to clindamycin, and after 6 weeks, the patient received maintenance therapy. Antiretroviral therapy with lamivudine, stavudine, and indinavir was then started. The response was excellent, and in the following 18 months, the CD4 cell count progressively increased to 11100/ mm 3 , and her plasma viral load was permanently suppressed (as measured by an ultrasensitive assay [Amplicor; Roche Diagnostic Systems, Rotkreuz, Switzerland]).
After 22 months, the patient insisted that her maintenance therapy for toxoplasmic encephalitis be discontinued to reduce her pill load of 20 tablets a day. At this time, a CT scan showed a 1.7-cm diameter cerebral lesion with calcification that was identical to that on a previous CT scan at a 12-month followup. Twelve months after discontinuation of secondary prophylaxis for T. gondii infection, the patient had no clinical signs of relapse, and her CT scan remained unchanged ( figure 1B) . Data from observational studies on the discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia in patients with persistent CD4 lymphocyte counts 1200/mm 3 and antibodies to T. gondii have shown that no relapses of P. carinii pneumonia and T. gondii infection occurred [3, 4] . However, the number of patients with antibodies to T. gondii was too small to allow for firm conclusions as to whether discontinuation of primary prophylaxis for toxoplasmic encephalitis is safe.
Discontinuation of maintenance therapy for patients with established toxoplasmic encephalitis is not recommended [5] . Relapse rates after discontinuation of maintenance therapy, as reported from the pre-HAART era, may be у50% [2] . However, secondary prophylaxis for toxoplasmic encephalitis is all but satisfactory. Rates of breakthrough relapses associated with sulfadiazine and pyrimethamine, the most effective drug combination, are 10%-40%, and rates of drug-limiting toxicity associated with this combination are 30%-43% [2] .
Because of side effects, high pill load, and drug interactions, discontinuation of maintenance therapy for toxoplasmosis after immune restoration with HAART is likely to improve the quality of life in patients with AIDS and to increase adherence to antiretroviral therapy. Therefore, studies evaluating whether secondary prophylaxis for toxoplasmic encephalitis may be discontinued for selected patients with excellent response to HAART seem timely. 
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